Premium
Managing Innovation to Maximize Value Along the Discovery‐Translation‐Application Continuum
Author(s) -
Waldman SA,
Terzic A
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.551
Subject(s) - biopharmaceutical , drug development , portfolio , bench to bedside , drug discovery , risk analysis (engineering) , identification (biology) , medicine , business , engineering ethics , computer science , engineering , medical physics , drug , pharmacology , microbiology and biotechnology , bioinformatics , botany , finance , biology
Success in pharmaceutical development led to a record 51 drugs approved in the past year, surpassing every previous year since 1950. Technology innovation enabled identification and exploitation of increasingly precise disease targets ensuring next generation diagnostic and therapeutic products for patient management. The expanding biopharmaceutical portfolio stands, however, in contradistinction to the unsustainable costs that reflect remarkable challenges of clinical development programs. This annual Therapeutic Innovations issue juxtaposes advances in translating molecular breakthroughs into transformative therapies with essential considerations for lowering attrition and improving the cost‐effectiveness of the drug‐development paradigm. Realizing the discovery‐translation‐application continuum mandates a congruent approval, adoption, and access triad.